Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2012

Conditions
Glioma
Interventions
DRUG

vinblastine sulphate injection

Vinblastine dose: 6 mg/m\^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.

Trial Locations (1)

M5G 1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

Ontario Cancer Research Network

NETWORK

lead

The Hospital for Sick Children

OTHER

NCT00213278 - Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma | Biotech Hunter | Biotech Hunter